Formulations in early clinical development require a delicate balance of flexibility, simplicity, and scientific rigor. In first‑in‑human trials, dose ranges can vary by 10–100 fold increase between the starting dose a...

Join us to explore the latest best practices in global flow cytometry QC and harmonisation. During this webinar hosted by Bioanalysis Zone ICON’s flow cytometry specialists will discuss: - Industry best practices for h...

Join ICON at #OCT Southeast on 10–11 March to explore how we support biotech organizations with flexible clinical development solutions, operational expertise and data driven decision making. Visit Booth #37 to meet ou...

Latest issue out now. Keep up to date on the most recent regulatory changes in the world of pharma, biotech and medical device clinical trials with ICON’s Regulatory Intelligence Newsletter. Join thousands of subscribe...

Sponsors with multi-indication assets can benefit from taking a precision approach to patient screening that enables stratification by relevant comorbidities and related factors. Learn more trial design considerations ...

At #OCT Southeast on 10–11 March, ICON will showcase the operational, scientific and digital expertise that helps biotechs navigate complexity and deliver studies with greater certainty. Visit Booth \#37 to speak with ...

Non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. This article in SelectScience® Science explores the evolving NIT landscape, emerging...

Join Luke Gregory at #ACDM26 as he explores why artificial intelligence is only one part of a truly effective clinical data science toolkit. Drawing on practical examples, he will show how thoughtful problem assessment, ...

Flow cytometry is rapidly evolving - driven by high parameter and spectral technologies, smarter data analytics and global standardisation efforts. This Spotlight hosted by Bioanalysis Zone brings together leading expe...

Ultra rare disease progress does not happen by accident. Register for our webinar to hear how patient leaders are accelerating therapies and redefining what is possible through practical, repeatable expert‑proven model...

Patient leadership is a catalyst for innovation in ultra rare diseases. Hear directly from leaders who are challenging regulatory norms, driving first in human treatments and bringing hope and treatments to families fast...

Heading to ADPD 2026? Visit ICON at booth \#29 to discuss how our early development and neuroscience teams support more informed decision making in neurodegenerative research. With in house early phase capabilities and...